$PYXS News

Pyxis Oncology To Present Late-Breaking Oral Data On MICVO Monotherapy In Previously Treated Recurrent/Metastatic Head And Neck Cancer At EORTC-NCI-AACR Symposium

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

Pyxis Oncology stock falls on public offering announcement

Pyxis Oncology Announces Proposed Public Offering

Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed

Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement

Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery

Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8

HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma - Slideshow

Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript

Pyxis Oncology shares fall 7% despite updated MICVO trial results

Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug

Wells Fargo Maintains Overweight on Pyxis Oncology, Raises Price Target to $19

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Pyxis Oncology Announces Updated Data From Ongoing Global Phase 1 Monotherapy Study Evaluating Micvotabart Pelidotin In Patients With 2L+ R/M Head And Neck Squamous Cell Carcinoma

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Pyxis Oncology To Present Updated Phase 1 MICVO Data In Head And Neck Cancer On A Live Webcast On September 9, 2026 At 7:30 a.m. ET

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board